FDA Alerts

The FDA has expanded the indication for a drug formerly approved for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections.

The US Food and Drug Administration has approved a new oral liquid therapy for the treatment of Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated enterocolitis.

The US Food and Drug Administration has expanded a 2017 contraindication for opioid-containing cough and cold products, which initially only restricted their use in children younger than 12 years.

The US Food and Drug Administration has approved a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the improvement of glycemic control in adults with type 2 diabetes.

The US Food and Drug Administration has approved a new option to treat dangerously low blood pressure in adult patients with septic or other distributive shock.

The US Food and Drug Administration has approved a new treatment option for patients with open-angle glaucoma or ocular hypertension.

The US Food and Drug Administration recently approved a drug for the treatment of adults with active psoriatic arthritis.

The US Food and Drug Administration recently approved a biosimilar to a drug used for the treatment of various autoimmune diseases, including rheumatoid arthritis and Crohn disease.

The US Food and Drug Administration has recently approved the first treatment option for patients with eosinophilic granulomatosis with polyangiitis.

The FDA has approved a new option for the long-term maintenance treatment of airflow obstruction in individuals with chronic obstructive pulmonary disease.